The REWIND study met its primary efficacy endpoint, showing that administration of the GLP-1 RA dulaglutide once-weekly significantly reduces MACE versus placebo in adult diabetic patients with or without CVD.

This umbrella review of recent systematic reviews and meta-analyses compared the effectiveness and underlying mechanisms of various prevention and treatment strategies to regulate blood glucose.

In recent years, new insights into the CV risk associated with diabetes have resulted in a new management approach of T2DM. Prof. Deanfield explains the rationale of a multifactorial approach.

In a posthoc analysis of the LEADER trial, liraglutide treatment was associated with fewer CV outcomes patients with type 2 diabetes and chronic kidney disease at high CV risk.

CME accredited course focussed on the role of GLP-1 agonists in preventing cardiovascular disease in patients with T2DM. Member registration (free) is needed to enroll in this course

Prof. Jacob gives an overview of new antidiabetic interventions that showed a reduction in CV and total mortality in CV risk patients, which seems to be independent of improved glycemic control.

This is a summary of the presentation by dr. Filip K. Knop, in which he explains that GLP-1RA treatment has also beneficial effects beyond glucose metabolism in T2DM patients.

In obese individuals without diabetes, semaglutide significantly and dose-dependently reduced body weight compared with placebo and liraglutide, on top of healthy diet and exercise.

CME accredited course focussed on novel concepts and treatments of comorbidities in heart failure with preserved ejection fractions. Member registration (free) is needed to enroll in this course

Slides as educational service to PACE members and meeting participants

Slides as educational service to PACE members and meeting participants

Multiple pathways play a role in the development of T2DM. This is why targeting multiple processes may improve glucose regulation. Prof. Bailey gives an extensive overview of the available therapeutic options, discussing mechanisms, advantages and disadvantages.